Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study

Skin Cancer

Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study

Eur J Cancer

Mandalà M, Amaral T, Rutkowski P, Sergi MC, Rasch ML, Benannoune N, Serra P, Vitale MG, Giannarelli D, Arance AM, Couselo EM, Neyns B, Dirven I, Tucci M, Guida M, Spagnolo F, Rossi E, Queirolo P, Quaglino P, Depenni R, Placzke J, Giacomo AMD, Del Vecchio M, Indini A, Silva IPD, Menzies AM, Hong A, Lorigan P, Long GV, Robert C, Ascierto PA

doi: 10.1016/j.ejca.2025.115567

Lung, Respiratory and Thoracic Cancer

First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study

Lung Cancer

Shah R, Buchmeier EL, Kopp HG, Christoph DC, Griesinger F, Reck M, Hoffknecht P, Kuon J, Frost N, Grohé C, Faehling M, Luan J, Roeper J, Chesi P, Blasi M, Kimmich M, Olchers T, Bischoff H, Klotz LV, Chung I, Christopoulos P, Thomas M

doi: 10.1016/j.lungcan.2025.108702

Skin Cancer

Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study

Eur J Cancer

Albrecht LJ, Garnier J, Zaremba A, Brauch L, Brunnert F, Rauschenberg R, Forschner A, Vazquez XG, Mangana J, Erdmann M, Angela Y, Franklin C, Tietze J, Lodde G, Tasdogan A, Seier JA, Roesch A, Ugurel S, Berking C, Gutzmer R, Heinzerling L, Meier F, Mohr P, Hassel JC, Schadendorf D, Livingstone E, Zimmer L

doi: 10.1016/j.ejca.2026.116595

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

ESMO Open

Peters S, Salomonsen RJ, Diaz Perez I, Shcherbakova T, Wang A, Cai L, Sadow S, Liu SV

doi: 10.1016/j.esmoop.2025.106031

EHA 2025

Lymphoma

Real-world effectiveness and safety of second-line axi-cel in patients with R/R LBCL

Lung, Respiratory and Thoracic Cancer

Real-World Use and Immunotherapy Rechallenge Outcomes with Nivolumab in Advanced Non-small Cell Lung Cancer in France: Interim Results of the LIST Study

Oncol Ther

Godbert B, Gobbini E, Decroisette C, Lena H, Khalife Y, Brellier F, Fleuriet A, Zysman M, Egenod T, Moro Sibilot D, Girard N

doi: 10.1007/s40487-025-00381-z

ESMO 2025

Gastrointestinal Cancer

CheckMate 8HW: Nivolumab plus ipilimumab provides clinically meaningful benefits over nivolumab alone in MSI-H/dMMR-positive mCRC

Genitourinary Cancer

Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study

Ann Oncol

Motzer RJ, Albiges L, Aguirre SAT, Kanesvaran R, Centkowski P, Reimers MA, Sade JP, Pouessel D, Biscaldi E, Esteban E, Arranz Arija JÁ, Tykodi SS, van Kooten Losio M, Dighe A, Ma H, Valmeekam V, Simmons A, Scheffold C, Andrianova S, Braun DA, Powles T, Choueiri TK

doi: 10.1016/j.annonc.2026.02.011

Skin Cancer

A population-level real-world analysis and single-center validation of melanoma brain metastasis epidemiology following dual-agent immunotherapy

Clin Cancer Res

Bhanja D, Zhu J, Wilding H, Benavides-Vasquez J, de Macedo Filho L, Ozair A, Moeckel C, Badani A, Hong J, Sivik J, Drabick JJ, Pameijer CR, Margolin K, Ahluwalia M, Mansouri A

doi: 10.1158/1078-0432.CCR-24-2681

Related content

Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study

First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study

Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study

Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study

Real-world effectiveness and safety of second-line axi-cel in patients with R/R LBCL

Real-World Use and Immunotherapy Rechallenge Outcomes with Nivolumab in Advanced Non-small Cell Lung Cancer in France: Interim Results of the LIST Study

CheckMate 8HW: Nivolumab plus ipilimumab provides clinically meaningful benefits over nivolumab alone in MSI-H/dMMR-positive mCRC

Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study

A population-level real-world analysis and single-center validation of melanoma brain metastasis epidemiology following dual-agent immunotherapy